471 related articles for article (PubMed ID: 16343775)
1. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.
Yamaguchi Y; Nishimura M; Nagano M; Yagi H; Sasakawa H; Uchida K; Shitara K; Kato K
Biochim Biophys Acta; 2006 Apr; 1760(4):693-700. PubMed ID: 16343775
[TBL] [Abstract][Full Text] [Related]
2. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
3. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
Matsumiya S; Yamaguchi Y; Saito J; Nagano M; Sasakawa H; Otaki S; Satoh M; Shitara K; Kato K
J Mol Biol; 2007 May; 368(3):767-79. PubMed ID: 17368483
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
Krapp S; Mimura Y; Jefferis R; Huber R; Sondermann P
J Mol Biol; 2003 Jan; 325(5):979-89. PubMed ID: 12527303
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
7. Site-specific N-glycosylation of chicken serum IgG.
Suzuki N; Lee YC
Glycobiology; 2004 Mar; 14(3):275-92. PubMed ID: 14693911
[TBL] [Abstract][Full Text] [Related]
8. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
Mimura Y; Church S; Ghirlando R; Ashton PR; Dong S; Goodall M; Lund J; Jefferis R
Mol Immunol; 2000; 37(12-13):697-706. PubMed ID: 11275255
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
10. NMR assignments of the N-glycans of the Fc fragment of mouse immunoglobulin G2b glycoprotein.
Yanaka S; Yamaguchi Y; Takizawa T; Miyanoiri Y; Yogo R; Shimada I; Kato K
Biomol NMR Assign; 2021 Apr; 15(1):187-192. PubMed ID: 33423189
[TBL] [Abstract][Full Text] [Related]
11. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.
Mimura Y; Ashton PR; Takahashi N; Harvey DJ; Jefferis R
J Immunol Methods; 2007 Sep; 326(1-2):116-26. PubMed ID: 17714731
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
13. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
15. Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding.
Subedi GP; Hanson QM; Barb AW
Structure; 2014 Oct; 22(10):1478-88. PubMed ID: 25199692
[TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.
Zou G; Ochiai H; Huang W; Yang Q; Li C; Wang LX
J Am Chem Soc; 2011 Nov; 133(46):18975-91. PubMed ID: 22004528
[TBL] [Abstract][Full Text] [Related]
17. The Structural Role of Antibody N-Glycosylation in Receptor Interactions.
Subedi GP; Barb AW
Structure; 2015 Sep; 23(9):1573-1583. PubMed ID: 26211613
[TBL] [Abstract][Full Text] [Related]
18. Isotype and glycoform selection for antibody therapeutics.
Jefferis R
Arch Biochem Biophys; 2012 Oct; 526(2):159-66. PubMed ID: 22465822
[TBL] [Abstract][Full Text] [Related]
19. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
